 | • レポートコード：B-GIR08C5677 • 出版社/出版日：GlobalInfoResearch / 2019年8月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、136ページ • 納品方法：Eメール • 産業分類：Pharma & Healthcare |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは、多発性骨髄腫用標的治療薬の世界市場について調べ、まとめました。種類別セグメントは、免疫調節剤、プロテアソーム阻害剤、ヒストンデアセチラーゼ阻害剤（HDACI）、モノクローナル抗体、その他等、用途別セグメントは、異種LAN、LAN及びWAN相互接続、WAN及びWAN相互接続、LAN及びホスト相互接続、その他等に区分しました。多発性骨髄腫用標的治療薬の世界市場概観、企業動向、企業別多発性骨髄腫用標的治療薬シェア、市場規模推移、市場規模予測（2019年-2024年）、主要地域分析（北米、ヨーロッパ、アジア等）、主要国分析（日本、中国、アメリカ等）データなどの情報が含まれています。 ・多発性骨髄腫用標的治療薬の市場概観 ・多発性骨髄腫用標的治療薬の企業概要（事業概要、製品種類、販売量、価格、売上、市場シェア等） ・多発性骨髄腫用標的治療薬の企業別販売動向、市場シェア、市場集中度、競争動向 ・多発性骨髄腫用標的治療薬の世界市場規模 ・多発性骨髄腫用標的治療薬の北米市場分析（アメリカ、カナダ、メキシコ等） ・多発性骨髄腫用標的治療薬のアメリカ市場規模推移 ・多発性骨髄腫用標的治療薬のカナダ市場規模推移 ・多発性骨髄腫用標的治療薬のメキシコ市場規模推移 ・多発性骨髄腫用標的治療薬のヨーロッパ市場分析（ドイツ、イギリス、ロシア、フランス、イタリア等） ・多発性骨髄腫用標的治療薬のドイツ市場規模推移 ・多発性骨髄腫用標的治療薬のイギリス市場規模推移 ・多発性骨髄腫用標的治療薬のロシア市場規模推移 ・多発性骨髄腫用標的治療薬のアジア太平洋市場分析（日本、中国、韓国、インド、東南アジア等） ・多発性骨髄腫用標的治療薬の日本市場規模推移 ・多発性骨髄腫用標的治療薬の中国市場規模推移 ・多発性骨髄腫用標的治療薬の韓国市場規模推移 ・多発性骨髄腫用標的治療薬のインド市場規模推移 ・多発性骨髄腫用標的治療薬の東南アジア市場規模推移 ・多発性骨髄腫用標的治療薬の南米市場分析（ブラジル、アルゼンチン等） ・多発性骨髄腫用標的治療薬の中東・アフリカ市場分析（サウジアラビア、UAE、南アフリカ等） ・多発性骨髄腫用標的治療薬の種類別分析/販売量、売上、市場シェア（免疫調節剤、プロテアソーム阻害剤、ヒストンデアセチラーゼ阻害剤（HDACI）、モノクローナル抗体、その他） ・多発性骨髄腫用標的治療薬の用途別分析/市場規模（異種LAN、LAN及びWAN相互接続、WAN及びWAN相互接続、LAN及びホスト相互接続、その他） ・多発性骨髄腫用標的治療薬の市場予測2019年-2024年（地域別予測、種類別予測、用途別予測） ・多発性骨髄腫用標的治療薬の販売チャネル・代理店・貿易業者・ディーラー分析 |
Scope of the Report:
The global Targeted Drugs for Multiple Myeloma market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Targeted Drugs for Multiple Myeloma.
Europe also play important roles in global market, with market size of xx million USD in 2019 and will be xx million USD in 2024, with a CAGR of xx%.
This report studies the Targeted Drugs for Multiple Myeloma market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Targeted Drugs for Multiple Myeloma market by product type and applications/end industries.
Market Segment by Companies, this report covers
Celgene
SL Pharma
Natco Pharma
Intas Pharmaceuticals
Indiabulls Pharmaceutical
Cipla
Glenmark Pharmaceuticals
Dr Reddy’s Laboratories
Qilu Pharmaceutical
Chia Tai-Tianqing
Hanson Pharm
Meidakang Huakang Pharmaceutical
Shandong Kongfu Pharmaceutical
J&J
Takeda
Amgen
Bristol Myers Squibb
Abbvie
Seattle Genetics
Karyopharm Therapeutics
PDL BioPharma
Roche
Sumitomo
Merck
Biogen
Schering-Plough
Glaxo
Chiron
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Immunomodulator
Proteasome Inhibitors
Histone Deacetylase Inhibitors (HDACI)
Monoclonal Antibody
Other
Market Segment by Applications, can be divided into
Hospital
Drug Center
Clinic
Other
Table of Contents
1 Targeted Drugs for Multiple Myeloma Market Overview
1.1 Product Overview and Scope of Targeted Drugs for Multiple Myeloma
1.2 Classification of Targeted Drugs for Multiple Myeloma by Types
1.2.1 Global Targeted Drugs for Multiple Myeloma Revenue Comparison by Types (2019-2024)
1.2.2 Global Targeted Drugs for Multiple Myeloma Revenue Market Share by Types in 2018
1.2.3 Immunomodulator
1.2.4 Proteasome Inhibitors
1.2.5 Histone Deacetylase Inhibitors (HDACI)
1.2.6 Monoclonal Antibody
1.2.7 Other
1.3 Global Targeted Drugs for Multiple Myeloma Market by Application
1.3.1 Global Targeted Drugs for Multiple Myeloma Market Size and Market Share Comparison by Applications (2014-2024)
1.3.2 Hospital
1.3.3 Drug Center
1.3.4 Clinic
1.3.5 Other
1.4 Global Targeted Drugs for Multiple Myeloma Market by Regions
1.4.1 Global Targeted Drugs for Multiple Myeloma Market Size (Million USD) Comparison by Regions (2014-2024)
1.4.1 North America (USA, Canada and Mexico) Targeted Drugs for Multiple Myeloma Status and Prospect (2014-2024)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Targeted Drugs for Multiple Myeloma Status and Prospect (2014-2024)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Targeted Drugs for Multiple Myeloma Status and Prospect (2014-2024)
1.4.4 South America (Brazil, Argentina, Colombia) Targeted Drugs for Multiple Myeloma Status and Prospect (2014-2024)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Targeted Drugs for Multiple Myeloma Status and Prospect (2014-2024)
1.5 Global Market Size of Targeted Drugs for Multiple Myeloma (2014-2024)
2 Manufacturers Profiles
2.1 Celgene
2.1.1 Business Overview
2.1.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Celgene Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.2 SL Pharma
2.2.1 Business Overview
2.2.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 SL Pharma Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.3 Natco Pharma
2.3.1 Business Overview
2.3.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Natco Pharma Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.4 Intas Pharmaceuticals
2.4.1 Business Overview
2.4.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Intas Pharmaceuticals Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.5 Indiabulls Pharmaceutical
2.5.1 Business Overview
2.5.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Indiabulls Pharmaceutical Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.6 Cipla
2.6.1 Business Overview
2.6.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Cipla Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.7 Glenmark Pharmaceuticals
2.7.1 Business Overview
2.7.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Glenmark Pharmaceuticals Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.8 Dr Reddy’s Laboratories
2.8.1 Business Overview
2.8.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Dr Reddy’s Laboratories Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.9 Qilu Pharmaceutical
2.9.1 Business Overview
2.9.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Qilu Pharmaceutical Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.10 Chia Tai-Tianqing
2.10.1 Business Overview
2.10.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Chia Tai-Tianqing Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.11 Hanson Pharm
2.11.1 Business Overview
2.11.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.11.2.1 Product A
2.11.2.2 Product B
2.11.3 Hanson Pharm Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.12 Meidakang Huakang Pharmaceutical
2.12.1 Business Overview
2.12.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.12.2.1 Product A
2.12.2.2 Product B
2.12.3 Meidakang Huakang Pharmaceutical Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.13 Shandong Kongfu Pharmaceutical
2.13.1 Business Overview
2.13.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.13.2.1 Product A
2.13.2.2 Product B
2.13.3 Shandong Kongfu Pharmaceutical Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.14 J&J
2.14.1 Business Overview
2.14.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.14.2.1 Product A
2.14.2.2 Product B
2.14.3 J&J Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.15 Takeda
2.15.1 Business Overview
2.15.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.15.2.1 Product A
2.15.2.2 Product B
2.15.3 Takeda Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.16 Amgen
2.16.1 Business Overview
2.16.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.16.2.1 Product A
2.16.2.2 Product B
2.16.3 Amgen Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.17 Bristol Myers Squibb
2.17.1 Business Overview
2.17.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.17.2.1 Product A
2.17.2.2 Product B
2.17.3 Bristol Myers Squibb Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.18 Abbvie
2.18.1 Business Overview
2.18.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.18.2.1 Product A
2.18.2.2 Product B
2.18.3 Abbvie Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.19 Seattle Genetics
2.19.1 Business Overview
2.19.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.19.2.1 Product A
2.19.2.2 Product B
2.19.3 Seattle Genetics Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.20 Karyopharm Therapeutics
2.20.1 Business Overview
2.20.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.20.2.1 Product A
2.20.2.2 Product B
2.20.3 Karyopharm Therapeutics Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.21 PDL BioPharma
2.21.1 Business Overview
2.2.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.21.2.1 Product A
2.21.2.2 Product B
2.21.3 PDL BioPharma Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.22 Roche
2.22.1 Business Overview
2.22.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.22.2.1 Product A
2.22.2.2 Product B
2.22.3 Roche Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.23 Sumitomo
2.23.1 Business Overview
2.23.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.23.2.1 Product A
2.23.2.2 Product B
2.23.3 Sumitomo Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.24 Merck
2.24.1 Business Overview
2.24.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.24.2.1 Product A
2.24.2.2 Product B
2.24.3 Merck Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.25 Biogen
2.25.1 Business Overview
2.25.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.25.2.1 Product A
2.25.2.2 Product B
2.25.3 Biogen Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.26 Schering-Plough
2.26.1 Business Overview
2.26.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.26.2.1 Product A
2.26.2.2 Product B
2.26.3 Schering-Plough Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.27 Glaxo
2.27.1 Business Overview
2.27.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.27.2.1 Product A
2.27.2.2 Product B
2.27.3 Glaxo Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.28 Chiron
2.28.1 Business Overview
2.28.2 Targeted Drugs for Multiple Myeloma Type and Applications
2.28.2.1 Product A
2.28.2.2 Product B
2.28.3 Chiron Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
3 Global Targeted Drugs for Multiple Myeloma Market Competition, by Players
3.1 Global Targeted Drugs for Multiple Myeloma Revenue and Share by Players (2014-2019)
3.2 Market Concentration Rate
3.2.1 Top 5 Targeted Drugs for Multiple Myeloma Players Market Share
3.2.2 Top 10 Targeted Drugs for Multiple Myeloma Players Market Share
3.3 Market Competition Trend
4 Global Targeted Drugs for Multiple Myeloma Market Size by Regions
4.1 Global Targeted Drugs for Multiple Myeloma Revenue and Market Share by Regions
4.2 North America Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
4.3 Europe Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
4.4 Asia-Pacific Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
4.5 South America Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
4.6 Middle East and Africa Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
5 North America Targeted Drugs for Multiple Myeloma Revenue by Countries
5.1 North America Targeted Drugs for Multiple Myeloma Revenue by Countries (2014-2019)
5.2 USA Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
5.3 Canada Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
5.4 Mexico Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
6 Europe Targeted Drugs for Multiple Myeloma Revenue by Countries
6.1 Europe Targeted Drugs for Multiple Myeloma Revenue by Countries (2014-2019)
6.2 Germany Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
6.3 UK Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
6.4 France Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
6.5 Russia Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
6.6 Italy Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
7 Asia-Pacific Targeted Drugs for Multiple Myeloma Revenue by Countries
7.1 Asia-Pacific Targeted Drugs for Multiple Myeloma Revenue by Countries (2014-2019)
7.2 China Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
7.3 Japan Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
7.4 Korea Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
7.5 India Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
7.6 Southeast Asia Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
8 South America Targeted Drugs for Multiple Myeloma Revenue by Countries
8.1 South America Targeted Drugs for Multiple Myeloma Revenue by Countries (2014-2019)
8.2 Brazil Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
8.3 Argentina Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
8.4 Colombia Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
9 Middle East and Africa Revenue Targeted Drugs for Multiple Myeloma by Countries
9.1 Middle East and Africa Targeted Drugs for Multiple Myeloma Revenue by Countries (2014-2019)
9.2 Saudi Arabia Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
9.3 UAE Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
9.4 Egypt Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
9.5 Nigeria Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
9.6 South Africa Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
10 Global Targeted Drugs for Multiple Myeloma Market Segment by Type
10.1 Global Targeted Drugs for Multiple Myeloma Revenue and Market Share by Type (2014-2019)
10.2 Global Targeted Drugs for Multiple Myeloma Market Forecast by Type (2019-2024)
10.3 Immunomodulator Revenue Growth Rate (2014-2024)
10.4 Proteasome Inhibitors Revenue Growth Rate (2014-2024)
10.5 Histone Deacetylase Inhibitors (HDACI) Revenue Growth Rate (2014-2024)
10.6 Monoclonal Antibody Revenue Growth Rate (2014-2024)
10.7 Other Revenue Growth Rate (2014-2024)
11 Global Targeted Drugs for Multiple Myeloma Market Segment by Application
11.1 Global Targeted Drugs for Multiple Myeloma Revenue Market Share by Application (2014-2019)
11.2 Targeted Drugs for Multiple Myeloma Market Forecast by Application (2019-2024)
11.3 Hospital Revenue Growth (2014-2019)
11.4 Drug Center Revenue Growth (2014-2019)
11.5 Clinic Revenue Growth (2014-2019)
11.6 Other Revenue Growth (2014-2019)
12 Global Targeted Drugs for Multiple Myeloma Market Size Forecast (2019-2024)
12.1 Global Targeted Drugs for Multiple Myeloma Market Size Forecast (2019-2024)
12.2 Global Targeted Drugs for Multiple Myeloma Market Forecast by Regions (2019-2024)
12.3 North America Targeted Drugs for Multiple Myeloma Revenue Market Forecast (2019-2024)
12.4 Europe Targeted Drugs for Multiple Myeloma Revenue Market Forecast (2019-2024)
12.5 Asia-Pacific Targeted Drugs for Multiple Myeloma Revenue Market Forecast (2019-2024)
12.6 South America Targeted Drugs for Multiple Myeloma Revenue Market Forecast (2019-2024)
12.7 Middle East and Africa Targeted Drugs for Multiple Myeloma Revenue Market Forecast (2019-2024)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
Figure Targeted Drugs for Multiple Myeloma Picture
Table Product Specifications of Targeted Drugs for Multiple Myeloma
Table Global Targeted Drugs for Multiple Myeloma and Revenue (Million USD) Market Split by Product Type
Figure Global Targeted Drugs for Multiple Myeloma Revenue Market Share by Types in 2018
Figure Immunomodulator Picture
Figure Proteasome Inhibitors Picture
Figure Histone Deacetylase Inhibitors (HDACI) Picture
Figure Monoclonal Antibody Picture
Figure Other Picture
Table Global Targeted Drugs for Multiple Myeloma Revenue (Million USD) by Application (2014-2024)
Figure Targeted Drugs for Multiple Myeloma Revenue Market Share by Applications in 2018
Figure Hospital Picture
Figure Drug Center Picture
Figure Clinic Picture
Figure Other Picture
Table Global Market Targeted Drugs for Multiple Myeloma Revenue (Million USD) Comparison by Regions 2014-2024
Figure North America Targeted Drugs for Multiple Myeloma Revenue (Million USD) and Growth Rate (2014-2024)
Figure Europe Targeted Drugs for Multiple Myeloma Revenue (Million USD) and Growth Rate (2014-2024)
Figure Asia-Pacific Targeted Drugs for Multiple Myeloma Revenue (Million USD) and Growth Rate (2014-2024)
Figure South America Targeted Drugs for Multiple Myeloma Revenue (Million USD) and Growth Rate (2014-2024)
Figure Middle East and Africa Targeted Drugs for Multiple Myeloma Revenue (Million USD) and Growth Rate (2014-2024)
Figure Global Targeted Drugs for Multiple Myeloma Revenue (Million USD) and Growth Rate (2014-2024)
Table Celgene Basic Information, Manufacturing Base and Competitors
Table Celgene Targeted Drugs for Multiple Myeloma Type and Applications
Table Celgene Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
Table SL Pharma Basic Information, Manufacturing Base and Competitors
Table SL Pharma Targeted Drugs for Multiple Myeloma Type and Applications
Table SL Pharma Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
Table Natco Pharma Basic Information, Manufacturing Base and Competitors
Table Natco Pharma Targeted Drugs for Multiple Myeloma Type and Applications
Table Natco Pharma Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
Table Intas Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table Intas Pharmaceuticals Targeted Drugs for Multiple Myeloma Type and Applications
Table Intas Pharmaceuticals Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
Table Indiabulls Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table Indiabulls Pharmaceutical Targeted Drugs for Multiple Myeloma Type and Applications
Table Indiabulls Pharmaceutical Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
Table Cipla Basic Information, Manufacturing Base and Competitors
Table Cipla Targeted Drugs for Multiple Myeloma Type and Applications
Table Cipla Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
Table Glenmark Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table Glenmark Pharmaceuticals Targeted Drugs for Multiple Myeloma Type and Applications
Table Glenmark Pharmaceuticals Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
Table Dr Reddy's Laboratories Basic Information, Manufacturing Base and Competitors
Table Dr Reddy's Laboratories Targeted Drugs for Multiple Myeloma Type and Applications
Table Dr Reddy's Laboratories Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
Table Qilu Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table Qilu Pharmaceutical Targeted Drugs for Multiple Myeloma Type and Applications
Table Qilu Pharmaceutical Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
Table Chia Tai-Tianqing Basic Information, Manufacturing Base and Competitors
Table Chia Tai-Tianqing Targeted Drugs for Multiple Myeloma Type and Applications
Table Chia Tai-Tianqing Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
Table Hanson Pharm Basic Information, Manufacturing Base and Competitors
Table Hanson Pharm Targeted Drugs for Multiple Myeloma Type and Applications
Table Hanson Pharm Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
Table Meidakang Huakang Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table Meidakang Huakang Pharmaceutical Targeted Drugs for Multiple Myeloma Type and Applications
Table Meidakang Huakang Pharmaceutical Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
Table Shandong Kongfu Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table Shandong Kongfu Pharmaceutical Targeted Drugs for Multiple Myeloma Type and Applications
Table Shandong Kongfu Pharmaceutical Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
Table J&J Basic Information, Manufacturing Base and Competitors
Table J&J Targeted Drugs for Multiple Myeloma Type and Applications
Table J&J Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
Table Takeda Basic Information, Manufacturing Base and Competitors
Table Takeda Targeted Drugs for Multiple Myeloma Type and Applications
Table Takeda Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
Table Amgen Basic Information, Manufacturing Base and Competitors
Table Amgen Targeted Drugs for Multiple Myeloma Type and Applications
Table Amgen Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
Table Bristol Myers Squibb Basic Information, Manufacturing Base and Competitors
Table Bristol Myers Squibb Targeted Drugs for Multiple Myeloma Type and Applications
Table Bristol Myers Squibb Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
Table Abbvie Basic Information, Manufacturing Base and Competitors
Table Abbvie Targeted Drugs for Multiple Myeloma Type and Applications
Table Abbvie Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
Table Seattle Genetics Basic Information, Manufacturing Base and Competitors
Table Seattle Genetics Targeted Drugs for Multiple Myeloma Type and Applications
Table Seattle Genetics Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
Table Karyopharm Therapeutics Basic Information, Manufacturing Base and Competitors
Table Karyopharm Therapeutics Targeted Drugs for Multiple Myeloma Type and Applications
Table Karyopharm Therapeutics Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
Table PDL BioPharma Basic Information, Manufacturing Base and Competitors
Table PDL BioPharma Targeted Drugs for Multiple Myeloma Type and Applications
Table PDL BioPharma Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
Table Roche Basic Information, Manufacturing Base and Competitors
Table Roche Targeted Drugs for Multiple Myeloma Type and Applications
Table Roche Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
Table Sumitomo Basic Information, Manufacturing Base and Competitors
Table Sumitomo Targeted Drugs for Multiple Myeloma Type and Applications
Table Sumitomo Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
Table Merck Basic Information, Manufacturing Base and Competitors
Table Merck Targeted Drugs for Multiple Myeloma Type and Applications
Table Merck Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
Table Biogen Basic Information, Manufacturing Base and Competitors
Table Biogen Targeted Drugs for Multiple Myeloma Type and Applications
Table Biogen Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
Table Schering-Plough Basic Information, Manufacturing Base and Competitors
Table Schering-Plough Targeted Drugs for Multiple Myeloma Type and Applications
Table Schering-Plough Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
Table Glaxo Basic Information, Manufacturing Base and Competitors
Table Glaxo Targeted Drugs for Multiple Myeloma Type and Applications
Table Glaxo Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
Table Chiron Basic Information, Manufacturing Base and Competitors
Table Chiron Targeted Drugs for Multiple Myeloma Type and Applications
Table Chiron Targeted Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
Table Global Targeted Drugs for Multiple Myeloma Revenue (Million USD) by Players (2014-2019)
Table Global Targeted Drugs for Multiple Myeloma Revenue Share by Players (2014-2019)
Figure Global Targeted Drugs for Multiple Myeloma Revenue Share by Players in 2017
Figure Global Targeted Drugs for Multiple Myeloma Revenue Share by Players in 2018
Figure Global Top 5 Players Targeted Drugs for Multiple Myeloma Revenue Market Share in 2018
Figure Global Top 10 Players Targeted Drugs for Multiple Myeloma Revenue Market Share in 2018
Figure Global Targeted Drugs for Multiple Myeloma Revenue (Million USD) and Growth Rate (%) (2014-2019)
Table Global Targeted Drugs for Multiple Myeloma Revenue (Million USD) by Regions (2014-2019)
Table Global Targeted Drugs for Multiple Myeloma Revenue Market Share by Regions (2014-2019)
Figure Global Targeted Drugs for Multiple Myeloma Revenue Market Share by Regions (2014-2019)
Figure Global Targeted Drugs for Multiple Myeloma Revenue Market Share by Regions in 2018
Figure North America Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
Figure Europe Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
Figure Asia-Pacific Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
Figure South America Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
Figure Middle East and Africa Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
Table North America Targeted Drugs for Multiple Myeloma Revenue by Countries (2014-2019)
Table North America Targeted Drugs for Multiple Myeloma Revenue Market Share by Countries (2014-2019)
Figure North America Targeted Drugs for Multiple Myeloma Revenue Market Share by Countries (2014-2019)
Figure North America Targeted Drugs for Multiple Myeloma Revenue Market Share by Countries in 2018
Figure USA Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
Figure Canada Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
Figure Mexico Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
Table Europe Targeted Drugs for Multiple Myeloma Revenue (Million USD) by Countries (2014-2019)
Figure Europe Targeted Drugs for Multiple Myeloma Revenue Market Share by Countries (2014-2019)
Figure Europe Targeted Drugs for Multiple Myeloma Revenue Market Share by Countries in 2018
Figure Germany Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
Figure UK Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
Figure France Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
Figure Russia Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
Figure Italy Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
Table Asia-Pacific Targeted Drugs for Multiple Myeloma Revenue (Million USD) by Countries (2014-2019)
Figure Asia-Pacific Targeted Drugs for Multiple Myeloma Revenue Market Share by Countries (2014-2019)
Figure Asia-Pacific Targeted Drugs for Multiple Myeloma Revenue Market Share by Countries in 2018
Figure China Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
Figure Japan Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
Figure Korea Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
Figure India Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
Figure Southeast Asia Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
Table South America Targeted Drugs for Multiple Myeloma Revenue by Countries (2014-2019)
Table South America Targeted Drugs for Multiple Myeloma Revenue Market Share by Countries (2014-2019)
Figure South America Targeted Drugs for Multiple Myeloma Revenue Market Share by Countries (2014-2019)
Figure South America Targeted Drugs for Multiple Myeloma Revenue Market Share by Countries in 2018
Figure Brazil Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
Figure Argentina Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
Figure Colombia Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
Table Middle East and Africa Targeted Drugs for Multiple Myeloma Revenue (Million USD) by Countries (2014-2019)
Table Middle East and Africa Targeted Drugs for Multiple Myeloma Revenue Market Share by Countries (2014-2019)
Figure Middle East and Africa Targeted Drugs for Multiple Myeloma Revenue Market Share by Countries (2014-2019)
Figure Middle East and Africa Targeted Drugs for Multiple Myeloma Revenue Market Share by Countries in 2018
Figure Saudi Arabia Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
Figure UAE Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
Figure Egypt Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
Figure Nigeria Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
Figure South Africa Targeted Drugs for Multiple Myeloma Revenue and Growth Rate (2014-2019)
Table Global Targeted Drugs for Multiple Myeloma Revenue (Million USD) by Type (2014-2019)
Table Global Targeted Drugs for Multiple Myeloma Revenue Share by Type (2014-2019)
Figure Global Targeted Drugs for Multiple Myeloma Revenue Share by Type (2014-2019)
Figure Global Targeted Drugs for Multiple Myeloma Revenue Share by Type in 2018
Table Global Targeted Drugs for Multiple Myeloma Revenue Forecast by Type (2019-2024)
Figure Global Targeted Drugs for Multiple Myeloma Market Share Forecast by Type (2019-2024)
Figure Global Immunomodulator Revenue Growth Rate (2014-2019)
Figure Global Proteasome Inhibitors Revenue Growth Rate (2014-2019)
Figure Global Histone Deacetylase Inhibitors (HDACI) Revenue Growth Rate (2014-2019)
Figure Global Monoclonal Antibody Revenue Growth Rate (2014-2019)
Figure Global Other Revenue Growth Rate (2014-2019)
Table Global Targeted Drugs for Multiple Myeloma Revenue by Application (2014-2019)
Table Global Targeted Drugs for Multiple Myeloma Revenue Share by Application (2014-2019)
Figure Global Targeted Drugs for Multiple Myeloma Revenue Share by Application (2014-2019)
Figure Global Targeted Drugs for Multiple Myeloma Revenue Share by Application in 2018
Table Global Targeted Drugs for Multiple Myeloma Revenue Forecast by Application (2019-2024)
Figure Global Targeted Drugs for Multiple Myeloma Market Share Forecast by Application (2019-2024)
Figure Global Hospital Revenue Growth Rate (2014-2019)
Figure Global Drug Center Revenue Growth Rate (2014-2019)
Figure Global Clinic Revenue Growth Rate (2014-2019)
Figure Global Other Revenue Growth Rate (2014-2019)
Figure Global Targeted Drugs for Multiple Myeloma Revenue (Million USD) and Growth Rate Forecast (2019-2024)
Table Global Targeted Drugs for Multiple Myeloma Revenue (Million USD) Forecast by Regions (2019-2024)
Figure Global Targeted Drugs for Multiple Myeloma Revenue Market Share Forecast by Regions (2019-2024)
Figure North America Targeted Drugs for Multiple Myeloma Revenue Market Forecast (2019-2024)
Figure Europe Targeted Drugs for Multiple Myeloma Revenue Market Forecast (2019-2024)
Figure Asia-Pacific Targeted Drugs for Multiple Myeloma Revenue Market Forecast (2019-2024)
Figure South America Targeted Drugs for Multiple Myeloma Revenue Market Forecast (2019-2024)
Figure Middle East and Africa Targeted Drugs for Multiple Myeloma Revenue Market Forecast (2019-2024)
多発性骨髄腫プロテアソーム阻害薬の世界市場予測 2024年：企業別、地域別、種類・用途別（～2024） Scope of the Report: The global Proteasome Inhibitors for Multiple Myeloma market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024. The Asia-Pacific will occupy for more market share in following years, esp…- 多発性骨髄腫における従来型化学療法薬の世界市場予測 2024年：企業別、地域別、種類・用途別（～2024） Scope of the Report: The global Traditional Chemotherapy Drugs for Multiple Myeloma market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024. The Asia-Pacific will occupy for more market share in following y…
- 世界の多発性骨髄腫の治療市場：市場規模・現状・予測 Multiple myeloma is a cancer formed due to malignant plasma cells. Normal plasma cells are found in the bone marrow and are an important part of the immune system. Plasma cells helps to fight infections by making antibodies that recognize and attack germs. Multiple myeloma causes cancer cells to acc…
- 多発性骨髄腫用免疫調節剤の世界市場予測 2024年：企業別、地域別、種類・用途別（～2024） Scope of the Report: The global Immunomodulator for Multiple Myeloma market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024. The Asia-Pacific will occupy for more market share in following years, especiall…
- 多発性骨髄腫に対するモノクローナル抗体の世界市場予測 2024年：企業別、地域別、種類・用途別（～2024） Scope of the Report: The global Monoclonal Antibody for Multiple Myeloma market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024. The Asia-Pacific will occupy for more market share in following years, espec…